ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib mesylate was the pioneering drug targeting this oncoprotein, marking a breakthrough in CML treatment due to its ability to inhibit the BCR::ABL1 TK domain [6,7].